+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase Not Applicable
Age: 18Years - 75Years
FEMALE
ID05179447

Phase III Study Comparing Molecular Profile-Based Treatment to Standard Radiation Therapy for Women with Early Stage Endometrioid Endometrial Cancer

Led by Women's Hospital School Of Medicine Zhejiang University · Updated on 2025-04-01

590

Participants Needed

10

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are investigating the use of integrated genomic-pathologic classification to guide adjuvant therapy decisions for women with early-stage endometrioid adenocarcinoma of the endometrium who have high-intermediate and intermediate risk features. This phase III randomized trial compares molecular profile-based treatment strategies with standard radiation therapy to better tailor treatment and potentially prevent overtreatment. The study builds on established risk factors and incorporates molecular-genetic information to refine patient care. Participants are assigned to different treatment groups based on their molecular and pathological profiles. One group receives no adjuvant therapy if they have a POLE-mutated profile, vaginal brachytherapy for an intermediate profile, or chemo-radiotherapy for a p53-abnormal profile. The comparator group receives standard treatment consisting of vaginal brachytherapy for intermediate risk cases and external beam pelvic radiotherapy for high-intermediate risk cases. The study treatments involve radiation methods such as vaginal brachytherapy, external beam radiotherapy, and chemotherapy combined with radiation. During the study, women undergo active follow-up including quality of life questionnaires and monitoring for cancer recurrence or progression over 3 to 5 years. Assessments include relapse-free survival, overall survival, adverse events, cancer-specific quality of life, and healthcare costs related to endometrial cancer. The primary outcome focuses on total cancer recurrence within three years. This comprehensive monitoring aims to evaluate the impact of personalized adjuvant therapy on patient outcomes over the study period.

CONDITIONS

Brief Title

PROfiling Based Endometrial Cancer Adjuvant Therapy

Research Team

X

Xinyu Wang, MD

Y

Yang Li, PhD

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here